Skip to main content

The pharmacotherapy of depression with EPA

This lecture considers the pharmacotherapy of depression with EPA under the following headings:

  • Epidemiological evidence

  • Biochemical evidence

  • First trial of pure EPA in severe treatment-resistant depression

  • Subsequent randomized double-blind placebo-controlled trials

  • Putative mechanisms.

Results obtained from our own group, including structural neuroimaging and 31-phosphorus neurospectroscopy findings, showing an association of EPA treatment of depression with a marked decrease in cerebral phosphodiesters, a marked increase in cerebral phosphomonoesters and reduced lateral ventricular volume, will also be presented.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Basant K Puri.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Puri, B.K. The pharmacotherapy of depression with EPA. Ann Gen Psychiatry 9, S23 (2010). https://doi.org/10.1186/1744-859X-9-S1-S23

Download citation

Keywords

  • Public Health
  • Marked Decrease
  • Ventricular Volume
  • Epidemiological Evidence
  • Biochemical Evidence